127 results
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
long-term incentives that are fully aligned with stockholders' interests in the pursuit of long-term value creation.
We’ve Made Significant Progress … restarted recruitment of the ongoing Phase 3 trial, which is a long-term event-driven trial design, and believe that celiprolol could address significant
424B3
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Prospectus supplement
4:23pm
pipeline could be accretive to our value proposition by potentially adding new clinical data catalysts and have the potential to create incremental long … -term value for stockholders. In addition, we believe that a multi-channel development program with several product candidates addressing various rare
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
) for oral suspension is a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults … -of-use assets
Goodwill
Long-term investments - other
Intangible assets, net
Other long-term assets
Total assets
Liabilities and stockholders’ equity
8-K/A
EX-99.3
0ich2uyojykptm 3n
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K
EX-99.1
kmt2gej74 ibcs8
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
424B5
03so85
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
EX-99.1
l3nfif6rbl5xw
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
tl53rnk
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-99.1
w3eox3j4u57b
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
8-K
EX-10.1
zpmjbokg76m8r
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
ksb4 xz8h
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
rtwqn4q
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
7lsklfoisllxd7d27d30
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
mb5 0u2mr
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
8s7c3
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-99.1
oaybs02661jj
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am